NCT00097396View on ClinicalTrials.gov

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

September 30, 2006

Conditions
Pneumonic PlaguePreventive Therapy
Interventions
BIOLOGICAL

rF1V vaccine

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
lead

DynPort Vaccine Company LLC, A GDIT Company

INDUSTRY

NCT00097396 - Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V | Biotech Hunter | Biotech Hunter